MTMT-ben szereplő publikációk tallózása szerző szerint "PhD Szociológia Doktori Iskola"

A találatok rendezése: Rendezés: Találatok:

  • Reshaping Social Capital During the Pandemic Crisis: Age Group Differences in Face‐to‐Face Contact Network Structures 
    Dávid, Beáta; Herke, Boglárka; Huszti, Éva; Tóth, Gergely; Túry-Angyal, Emese; Albert, Fruzsina (2023)
    This article presents findings about the impact of the first Covid‐related lockdown on the face‐to‐face (FTF) interpersonal contact networks of the Hungarian adult population. Our primary objective is to understand how the ...
  • Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries. 
    Zelei, Tamás; Molnar, Mária Judit; Szegedi, Márta; Kálo, Zoltán (2016)
    BACKGROUND: In case of orphan drugs applicability of the standard health technology assessment (HTA) process is limited due to scarcity of good clinical and health economic evidence. Financing these premium priced drugs ...
  • The European challenges of funding orphan medicinal products 
    Szegedi, Márta; Zelei, Tamás; Arickx, Francis; Bucsics, Anna; Cohn-Zanchetta, Emanuelle; Fürst, Jurij; Kamusheva, Maria; Kawalec, Pawel; Petrova, Guenka; Slaby, Juraj; Stawowczyk, Ewa; Vocelka, Milan; Zechmeister-Koss, Ingrid; Kaló, Zoltán; Molnár, Mária Judit (2018)
    Funding of orphan medicinal products (OMPs) is an increasing challenge in the European Union (EU).To identify the different methods for public funding of OMPs in order to map the availability for rare disease patients, as ...
  • The European challenges of funding orphan medicinal products 
    Szegedi, Márta; Zelei, Tamás; Arickx, Francis; Bucsics, Anna; Cohn-Zanchetta, Emanuelle; Fürst, Jurij; Kamusheva, Maria; Kawalec, Pawel; Petrova, Guenka; Slaby, Juraj; Stawowczyk, Ewa; Vocelka, Milan; Zechmeister-Koss, Ingrid; Kaló, Zoltán; Molnár, Mária Judit (2018)
    Funding of orphan medicinal products (OMPs) is an increasing challenge in the European Union (EU).To identify the different methods for public funding of OMPs in order to map the availability for rare disease patients, as ...